NASTAD has created a sign-on letter for Congressional leaders and appropriators asking that they allocate at least $100 million to CDC’s viral hepatitis program in FY2018. Congress included $6 billion over two years included in the Bipartisan Budget Act of 2018 to fight the nation’s opioid epidemic and this letter urges a portion of that funding goes to communities to deal with increasing hepatitis C, hepatitis B and HIV infections. For more information about the ask please see the letter. If your organization would like to be included please fill out this google form by next Wednesday, February 21st.
Advocacy, HepCX News, News
Governor Andrew M. Cuomo today announced the nation's first strategy to eliminate hepatitis C, including the establishment of a Hepatitis C Elimination Task Force that will advise the state as it implements its plan going forward.
Advocacy, Federal Budget, Sign On Letter
Ask your State Senator to sign on to the Senate Appropriations letter requesting additional funding for the Division of Viral Hepatitis at the CDC.
Advocacy, Hepatitis C
This Consensus statement was adopted at the NYS Hep C Elimination Summit and provides a statewide plan to eliminate Hep C.
Advocacy, Federal Budget, Hepatitis B, Medicare, Sign On Letter
Action from Hep B United, NVHR, the Hepatitis B Foundation, the National Task Force on Hepatitis B and others who have composed an organizational sign-on letter requesting initiation of National Coverage Determination process for including Hep B screening as a free Medicare preve...
Advocacy, Publications, Training
The primary goals of the Manual are to increase advocates' knowledge about available HCV tests and treatments and to jumpstart discussions on advocacy strategies that can be used to open up affordable access for more people with HCV.
The American Medical Association launched a website for consumers to tell their stories of how rising prices are affecting their health and their pocketbooks.
Advocacy, HepCX News, News, Hepatitis C, Medicaid, Open for Comment, Pharmaceutical
On February 26th, the New York State Drug Utilization Review Board will meet to review and recommend NYS Medicaid clinical criteria for Viekira Pak - the most recently approved Hepatitis C therapy - marketed by AbbVie.
- Hep C Task Force Meeting Highlights | 09-25-2019 October 10, 2019
- Job | Hep C Peer Navigator (Part-time) @ VOCAL-NY October 7, 2019
- Hep B Coalition Meeting Highlights | 09-18-19 October 7, 2019
- Job | Hep C Linkage to Care Specialist @ Brightpoint Health October 2, 2019
- NYC Rapid Hep C Testing Guidance and Resources October 1, 2019
- Job | Hep C Peer Navigator @ New York Harm Reduction Educators September 27, 2019
- Funding | Request for Proposal: Targeted Approach to Jail-Based Programs and Services (Department of Correction) September 24, 2019